Pfizer's earnings call highlighted a strong R&D pipeline and strategic focus on growth areas such as oncology and cardiometabolic segments, alongside significant growth in key products. However, the company also faced challenges, including a decline in overall revenue and potential impacts from global trade uncertainties and competition. Despite these challenges, Pfizer demonstrated strong operational efficiency and cost management, positioning itself for future growth.

Company Guidance -

Q1 2025

During Pfizer Inc.'s First Quarter 2025 Earnings Conference Call, the company reaffirmed its guidance for the fiscal year 2025, projecting total company revenues to be in the range of $61 to $64 billion and adjusted diluted earnings per share between $2.80 and $3.00. The call highlighted Pfizer's focus on improving R&D productivity, with anticipated milestones including at least four regulatory decisions and up to nine phase three readouts. The company reported first-quarter revenues of $13.7 billion, a 6% operational decline, primarily due to lower PAXLOVID revenues and changes in the IRA Medicare Part D redesign. However, Pfizer recorded strong growth in several key products, with adjusted diluted earnings per share reaching $0.92, attributed to robust gross margin and cost management. The company also emphasized its strategic priorities of enhancing shareholder value, maintaining a strong dividend policy, and pursuing disciplined capital allocation with reinvestments in R&D and potential external opportunities, despite the macroeconomic uncertainties such as potential tariffs and the complex global trade environment.

Strong R&D Pipeline and Strategic Focus

Pfizer emphasized strengthening its R&D organization with a focus on cardiometabolic and oncology segments. Anticipated multiple key milestones include at least four regulatory decisions and up to nine phase three readouts in 2025.

Significant Revenue Growth in Key Products

The Vintechl family of products saw robust growth, and the oncology portfolio, specifically Tatsit, grew by 25% in revenue. The company also reported a 40% revenue growth for Northrop America.

Operational Efficiency and Cost Management

Pfizer reported a 12% operational decline in total adjusted operating expenses and is on track to deliver $4.5 billion in cumulative net cost savings by the end of 2025.

Strong Performance in US and International Markets

Pfizer reported strong contributions across its product portfolio and noted significant market growth in international regions, particularly with products like Nortech, Tatsit, and Blurbbrand.

Pfizer (PFE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PFE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 05, 2025	2025 (Q2)	0.57 / -	0.6	―	―	―
Apr 29, 2025	2025 (Q1)	0.67 / 0.92	0.82	12.20% (+0.10)
Feb 04, 2025	2024 (Q4)	0.47 / 0.63	0.1	530.00% (+0.53)
Oct 29, 2024	2024 (Q3)	0.61 / 1.06	-0.17	723.53% (+1.23)
Jul 30, 2024	2024 (Q2)	0.46 / 0.60	0.67	-10.45% (-0.07)
May 01, 2024	2024 (Q1)	0.52 / 0.82	1.23	-33.33% (-0.41)
Jan 30, 2024	2023 (Q4)	-0.16 / 0.10	1.14	-91.23% (-1.04)
Oct 31, 2023	2023 (Q3)	-0.08 / -0.17	1.78	-109.55% (-1.95)
Aug 01, 2023	2023 (Q2)	0.57 / 0.67	2.04	-67.16% (-1.37)
May 02, 2023	2023 (Q1)	0.98 / 1.23	1.62	-24.07% (-0.39)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PFE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Apr 29, 2025	$22.62	$23.34	+3.18%
Feb 04, 2025	$25.71	$25.38	-1.28%
Oct 29, 2024	$27.43	$27.05	-1.39%
Jul 30, 2024	$29.20	$29.84	+2.19%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.